Login to Your Account



Flap in FAP as Ionis reports phase III, Alnylam's effort weighed

By Randy Osborne
Staff Writer

Monday, May 15, 2017

As developers of similar drugs sought signs of hope in the otherwise-favorable top-line phase III data with TTR antisense inhibitor inotersen in FAP, Ionis Pharmaceuticals Inc. called out during its conference call one would-be competitor's candidate by name: patisiran.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription